Complement inhibitor therapy in thymoma-associated myasthenia gravis: a real-world experience

Complement inhibitor therapy in thymoma-associated myasthenia gravis: a real-world experience

IntroductionThymoma-associated myasthenia gravis (TAMG) accounts for 15–20% of all myasthenia gravis (MG) cases and is typically characterized by severe clinical manifestations and suboptimal response to conventional therapies. However, TAMG patients are underrepresented in clinical trials, leaving...

Full description

Saved in:
Bibliographic Details
Main Authors: Sofia Marini, Carmen Erra, Laura Fionda, Silvia Falso, Elena Rossini, Federico Habetswallner, Elisa Meacci, Martina Marini, Francesco Habetswallner, Raffaele Iorio
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Immunology
Subjects:
thymoma
myasthenia gravis
complement inhibitors therapy
real-world
neuromuscular disease
neuroimmunology
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1562419/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1562419/full

Similar Items